4.22
+0.06(+1.44%)
Currency In USD
Address
2215 Yukon Street
Vancouver, BC V5Y 0A1
Canada
Phone
604 559 9005
Website
Sector
Healthcare
Industry
Biotechnology
Employees
596
First IPO Date
December 11, 2020
| Name | Title | Pay | Year Born |
| Dr. Carl L.G. Hansen Ph.D. | Chief Executive Officer, President & Chairperson | 746,836 | 1975 |
| Dr. Veronique Lecault Ph.D. | Chief Technology Officer & Director | 667,706 | 1985 |
| Mr. Andrew Booth M.B.A. | Chief Financial Officer | 671,720 | 1974 |
| Mr. Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer | 684,813 | 1971 |
| Mr. Tryn T. Stimart Esq., J.D., M.Sc. | Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer | 685,080 | 1970 |
| Marcie Thiessen CPA, CGA | Senior Director of Finance & Accounting | 0 | N/A |
| Mr. Murray McCutcheon Ph.D. | Senior Vice President of Partnering | 0 | N/A |
| Ms. Tiffany Chiu B.Sc., Ph.D. | Vice President of Communications | 0 | N/A |
| Graham Craig M.Sc. | Director of Corporate Development | 0 | N/A |
| Mr. Adam Clarke M.A.I.C.D., Ph.D. | Senior Vice President of Discovery | 0 | N/A |
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.